Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies (Details Narrative)

v3.20.1
Significant Accounting Policies (Details Narrative)
12 Months Ended
Nov. 25, 2019
Jul. 25, 2019
USD ($)
Dec. 31, 2019
USD ($)
Breathalyzers
Dec. 31, 2018
USD ($)
Breathalyzers
Reverse stock split On November 25, 2019, the Company effectuated a reverse stock split of its shares of Common Stock whereby every twenty-four (24) pre-split shares of Common Stock were exchanged for one (1) post-split share of the Company's Common Stock ("Reverse Stock Split").      
Restricted cash     $ 115,094 $ 500,000
Maturities of securities     less than one year  
Increase in unrealized gain on securities     $ 43,799  
Increase in unrealized loss on securities       25,913
Marketable securities gain (loss)     3,952 (15,178)
Proceeds from sale of marketable securities     2,857,960 6,313,330
Allowances for doubtful accounts for trade receivables     458,902 606,835
Bad debt expenses     5,325 185,335
Accrued liabilities     20,002 23,179
Rebates recognized during period     $ 130,577 105,247
Income tax examination, likelihood percentage     The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.  
Unrecognized tax benefits    
Income tax benefit    
Accrued for penalties and interest    
Product cost of sales     1,098,286 1,538,285
Cost of net revenue     46,534 93,558
Shipping and Handling [Member]        
Product cost of sales     $ 38,131 $ 50,518
Sales Revenue, Net [Member]        
Concentration risk percentage     79.00% 71.00%
Concentration risk, number of customer | Breathalyzers     2 2
Sales Revenue, Net [Member] | Customer One [Member]        
Concentration risk percentage     48.00% 57.00%
Sales Revenue, Net [Member] | Customer Two [Member]        
Concentration risk percentage     31.00% 14.00%
Trade Receivable [Member]        
Concentration risk percentage     83.00% 99.00%
Concentration risk, number of customer | Breathalyzers     5 2
Trade Receivable [Member] | Customer One [Member]        
Concentration risk percentage     30.00% 62.00%
Trade Receivable [Member] | Customer Two [Member]        
Concentration risk percentage     18.00% 37.00%
Trade Receivable [Member] | Customer Three [Member]        
Concentration risk percentage     12.00%  
Trade Receivable [Member] | Customer Four [Member]        
Concentration risk percentage     12.00%  
Trade Receivable [Member] | Customer Five [Member]        
Concentration risk percentage     11.00%  
Cost of Goods [Member] | Supplier One [Member]        
Concentration risk percentage     43.00% 14.00%
Concentration risk, number of supplier | Breathalyzers     1 1
Accounts Payable [Member] | No Supplier [Member]        
Concentration risk percentage     10.00% 10.00%
Concentration risk, number of supplier | Breathalyzers     0 0
Administrative Expenses [Member]        
Deposit reserve made     $ 100,000  
Unsecured Promissory Note [Member]        
Advances to related party   $ 100,000    
Maturity date   Oct. 02, 2019    
Minimum [Member]        
Normal credit terms extended to customers     30 days  
Maximum [Member]        
Normal credit terms extended to customers     90 days  
Long-lived intangible assets estimated useful lives     17 years